Form 8-K - Current report:
SEC Accession No. 0000950170-24-106820
Filing Date
2024-09-16
Accepted
2024-09-16 16:06:43
Documents
11
Period of Report
2024-09-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K dnth-20240916.htm   iXBRL 8-K 40005
  Complete submission text file 0000950170-24-106820.txt   195454

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dnth-20240916.xsd EX-101.SCH 57692
13 EXTRACTED XBRL INSTANCE DOCUMENT dnth-20240916_htm.xml XML 4698
Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Dianthus Therapeutics, Inc. /DE/ (Filer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 241301086
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)